IVIG (intravenous immunoglobulin) works in ITP primarily by flooding the body with antibodies that interfere with the immune system’s ability to destroy platelets. In immune thrombocytopenia, your immune system mistakenly tags platelets with autoantibodies, and immune cells in the spleen then clear those tagged platelets from circulation. IVIG disrupts this process through several overlapping mechanisms, raising platelet counts within days in roughly 70 to 90% of patients.
Blocking the Destruction Pathway
The most well-established mechanism involves something called Fc receptor blockade. Here’s what that means in plain terms: when your immune system marks a platelet for destruction, it attaches an antibody to the platelet’s surface. Immune cells in the spleen, called macrophages, have receptors that grab onto those antibodies and pull the platelet in to be destroyed. IVIG delivers a massive dose of normal, harmless antibodies that compete for those same receptors. The macrophages become saturated with IVIG antibodies and can no longer efficiently grab and destroy the antibody-coated platelets.
Think of it like filling a parking lot. Once every space is taken by IVIG antibodies, the autoantibodies stuck to your platelets have nowhere to dock, and the platelets survive longer in circulation.
Speeding Up Autoantibody Clearance
A second mechanism works on the autoantibodies themselves. Your body recycles antibodies through a receptor called FcRn, which rescues antibodies from being broken down and returns them to circulation. This is normally a useful system, but in ITP it also protects the harmful autoantibodies that are targeting your platelets. When IVIG floods the body with a large volume of normal antibodies, they compete with the autoantibodies for this recycling receptor. The autoantibodies lose the competition, get broken down faster, and their levels drop. Research suggests this competitive process accounts for a significant portion of the benefit IVIG provides.
Resetting Immune Regulation
Beyond these more immediate effects, IVIG also shifts the broader immune system toward a less aggressive state. It increases both the number and the suppressive power of regulatory T cells, a specialized population of immune cells that act as the body’s brakes on immune responses. In lab studies, exposing T cells to IVIG boosted their production of anti-inflammatory signaling molecules and increased expression of FOXP3, a protein that marks cells as regulatory. This pattern has been confirmed in patients with several autoimmune conditions.
IVIG also alters the behavior of dendritic cells, which are the immune cells responsible for deciding what the body should attack. By dampening dendritic cell activity and shifting cytokine networks toward anti-inflammatory signaling, IVIG helps reduce the overall autoimmune drive that keeps platelet counts low. These immunomodulatory effects are subtler and slower than receptor blockade, but they contribute to the overall response.
How Quickly Platelets Rise
IVIG is one of the fastest-acting treatments for ITP. In children, the median time for platelets to reach 50,000 per microliter is about 2 days after infusion, with counts reaching 100,000 in a median of 4 days. In a trial of adults receiving a standard two-day course, about 89% achieved platelet counts of 50,000 or higher within 7 days, and 92% reached at least 30,000 during the same period.
The American Society of Hematology recommends a starting dose of 1 g/kg given as a single infusion, though some situations call for a second dose on the following day. The infusion itself typically takes several hours, with the rate gradually increased as tolerated.
How Long the Effect Lasts
The platelet boost from IVIG is real but temporary. In a pediatric study, patients who initially achieved a complete response (platelets above 100,000) maintained it for a median of about 51 days before counts started dropping again. Some patients held their response for as little as 9 days, while others maintained it for over 3 months. This is why IVIG is often described as a bridge therapy: it buys time while other treatments take effect or while waiting for a procedure.
When IVIG Is the Preferred Choice
Steroids are the standard first-line treatment for ITP, but IVIG is preferred when speed matters. Active bleeding, preparation for surgery, or situations where a patient needs platelet counts raised within days rather than weeks are the main scenarios. In pregnancy, IVIG combined with steroids produces a faster response than steroids alone and reduces the need for platelet transfusions before delivery. IVIG can also be given alongside platelet transfusions during emergencies. The transfused platelets normally get destroyed quickly in ITP, but co-administering IVIG helps protect them long enough to stop bleeding.
Common and Rare Side Effects
Most side effects from IVIG are related to the infusion itself: headache, chills, nausea, and fatigue. These typically resolve within a day or two and can often be managed by slowing the infusion rate. Headache is the most frequent complaint, ranging from mild to severe.
Aseptic meningitis is an uncommon but notable reaction, linked to roughly 0.067% of all IVIG infusions. Symptoms include intense headache, neck stiffness, nausea, vomiting, light sensitivity, and fever. It can look alarming but resolves on its own, usually within a few days. There are no lasting neurological effects.
Hemolysis Risk and Blood Type
Because IVIG is manufactured from pooled donor plasma that includes blood from all ABO types, the product contains anti-A and anti-B antibodies. In patients with blood types A, B, or AB, these antibodies can attack red blood cells and cause hemolysis, a breakdown of red blood cells. Blood type O patients face almost no risk because their red blood cells lack the A and B markers these antibodies target.
The risk is highest in patients with blood type AB. One study found that 89% of AB patients experienced some degree of hemolysis compared to 33% of type A and 36% of type B patients. In a large adverse event database, 67% of reported hemolysis cases occurred in type A patients and 21% in type AB patients, with only 2% in type O. Higher doses increase the risk. Your care team will typically check your blood type and monitor for signs of hemolysis, which include dark urine, unexpected drops in hemoglobin, and fatigue that worsens after treatment rather than improving.